All In Biotech

Drug Trial Radar · NCT07150546

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Combination External Radiation and 177Lu-DOTATATE for Large Gastrointestinal Neuroendocrine Tumors: A Single Arm Pilot Clinical Trial

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Oct 14, 2025

Primary completion

Sep 30, 2026

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Sep 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety and effectiveness of stereotactic body radiation therapy (SBRT) followed by 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in treating patients with large well-differentiated grade 1-2 digestive system neuroendocrine tumors that cannot be removed by surgery (unresectable). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. 177Lu-DOTATATE is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. 177Lu-DOTATATE builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving PRRT after SBRT may reduce the chances of the disease returning or getting worse, compared to the standard treatment of PRRT alone.

Conditions

  • Digestive System Neuroendocrine Tumor
  • Unresectable Digestive System Neuroendocrine Neoplasm
  • Unresectable Digestive System Neuroendocrine Tumor G1
  • Unresectable Digestive System Neuroendocrine Tumor G2

Interventions

  • Stereotactic Body Radiation TherapyRadiation

    Undergo SBRT

  • Lutetium Lu 177 DotatateDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT and PET/CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Gallium Ga 68-DOTATATERadiation

    Undergo gallium Ga 68-DOTATATE PET/CT

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Acute Grade 3+ Non-Hematologic Adverse EventsTime frame: Within 3 months of therapy

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.